Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was up 5.9% on Friday . The company traded as high as $4.52 and last traded at $4.46, with a volume of 1,549,901 shares changing hands. The stock had previously closed at $4.21.

A number of equities research analysts have recently weighed in on KERX shares. Brean Capital lowered shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. FBR & Co reaffirmed an “outperform” rating and issued a $13.00 target price on shares of Keryx Biopharmaceuticals in a research report on Tuesday, May 17th. Cowen and Company reaffirmed a “neutral” rating on shares of Keryx Biopharmaceuticals in a research report on Wednesday. Maxim Group downgraded shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 1st. Finally, Zacks Investment Research downgraded shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the stock. Keryx Biopharmaceuticals has a consensus rating of “Hold” and an average target price of $8.79.

The firm’s 50 day moving average is $6.51 and its 200 day moving average is $5.20. The stock’s market cap is $475.13 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.14. The firm had revenue of $9.30 million for the quarter, compared to analyst estimates of $8.60 million. The business’s revenue was up 272.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.26) EPS. On average, analysts expect that Keryx Biopharmaceuticals Inc. will post ($1.21) EPS for the current year.

In other news, CFO Scott A. Holmes sold 4,935 shares of the company’s stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $7.36, for a total transaction of $36,321.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A hedge fund recently bought a new stake in Keryx Biopharmaceuticals stock. Royce & Associates LLC purchased a new stake in Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned approximately 0.32% of Keryx Biopharmaceuticals as of its most recent filing with the SEC.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.